Recombinant Human CD19 His-tag Protein, CF

Catalog #: 11095-CD Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
11095-CD-050

Recombinant Human CD19 His-tag Protein Binding Activity.

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human CD19 His-tag Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Human CD19 Antibody (FMC63) (Novus Biologicals, Catalog # NBP2-52716) is immobilized at 2.00 µg/mL (100 µL/well), Recombinant Human CD19 binds with an ED₅₀ of 15.0-150 ng/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived human CD19 protein

Human CD19 (Glu21-Lys291) Accession # P15391.6	6-His tag	IEGR
N-terminus		C-terminus

Accession #

P15391.6

N-terminal Sequence
Analysis

Glu21

Predicted Molecular Mass

31 kDa

SDS-PAGE

50-65 kDa, under reducing conditions.

Product Datasheets

11095-CD

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11095-CD

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

When Human CD19 Antibody (FMC63) (Novus Biologicals, Catalog # NBP2-52716) is immobilized at 2.00 µg/mL (100 µL/well), Recombinant Human CD19 His-tag Protein (Catalog # 11095-CD) binds with an ED₅₀ of 15.0‑50 ng/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human CD19 His-tag Protein (Catalog # 11095-CD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 50-65 kDa.

Reconstitution Calculator

Background: CD19

CD19, also known as B4, is a transmembrane glycoprotein of the immunoglobulin superfamily that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 consists of an extracellular domain (ECD) with two C2-type Ig-like domains, a transmembrane segment, and a cytoplasmic domain with nine tyrosine residues, 3 of which are critical for function (1, 2). Within the mature ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19. CD19 is expressed throughout B cell development from pre‑B cells through mature B cells, and it is commonly used as a B cell lineage marker (1, 2). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (1, 2). CD19 associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu-13 (1, 3). These associations enable CD19 to amplify B cell signaling and reduce the threshold for antigen stimulation through the BCR (1, 3). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors, such as leukemias and lymphomas (4, 5). Immunotherapy using a chimeric antigen receptor (CAR) targeting CD19 has emerged as promising therapeutic target for hematologic cancers and solid tumors, such as leukemias and lymphomas (4, 5). The first CD19 CAR T cell therapies have been granted FDA approval for the treatment of B cell malignancies with several more in clinical trials (6).

References

Wang, K. et al. (2012) Exp. Hematol. Oncol. 1:36.
Del Nargo, C.J. et al. (2005) Immunol Res. 31:229.
Yu, F. et al. (2010) J Neurooncol. 103:187.
Kochenderfer, J. et al. (2015) J. Clin. Oncol. 33:540.
Lee, D. et al. (2015) Lancet. 385:517.
Ahmad, A. et al. (2020) Int. J. Mol. Sci. 21:3906.

Entrez Gene IDs

930 (Human); 12478 (Mouse); 365367 (Rat); 397669 (Porcine); 607898 (Canine); 102145514 (Cynomolgus Monkey); 100147468 (Equine)

Alternate Names

B4; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; CD19 antigen; CD19 molecule; CD19; CVID3; Differentiation antigen CD19; Leu-12; MGC12802; T-cell surface antigen Leu-12